Business
Chancellor abandons planned income tax hike because of improved forecasts
The Chancellor has abandoned plans to hike income tax at the Budget because of improved economic forecasting.
Rachel Reeves had been expected to hike income tax in the face of a yawning gap in her spending plans, hinting as recently as Monday that the alternative would be “deep cuts” to public investment.
But reporting overnight claimed she has abandoned introducing an income tax rise at the November 26 Budget over fears it could anger both voters and backbench Labour MPs.
The PA news agency understands the strength of tax receipts has improved forecasting from the Office for Budget Responsibility, allowing for the U-turn.
This is particularly the case on stronger wage performance: the higher wages are, the more tax is paid on them.
A downgrade in productivity has also not been as bad as was first feared.
While Ms Reeves is no longer understood to be pursuing an income tax hike, tough choices are still said to lie ahead for the Government and other tax rises have not been ruled out.
Income tax thresholds could still be reduced while tax rates are kept the same, a move which could raise billions of pounds for the Treasury.
Limits to salary sacrifice schemes, as well as new measures to tax electric vehicles, are still in the mix as the Treasury pursues a “smorgasbord” approach of raising a range of smaller taxes.
The Chancellor has not changed her approach, it is understood, and still intends to give herself larger fiscal headroom – the buffer against economic headwinds which could impact Government spending plans.
The latest Budget measures were submitted last week, rather than being a knee-jerk response to the turmoil in No 10 this week sparked by a briefing war.
Ms Reeves has been laying the ground for tax rises over recent weeks, including during an early-morning speech on November 4 aimed at preparing the public for the Budget.
Downing Street insisted that the thrust of the speech “stands”.
The Prime Minister’s official spokesman said: “She was very clear about the challenges the country faces and her priorities in addressing those challenges.
“All of that still stands.”
The spokesman refused to comment on Budget speculation, but said the Chancellor will aim to “build more resilient public finances with the headroom to withstand global turbulence”.
This would “give businesses the confidence to invest and leaving the Government freer to act when the situation calls for it”, he added.
Government borrowing costs rose in the wake of the apparent U-turn on income tax on Friday morning.
Speculation about the change in direction sparked a sell-off in UK Government bonds, also known as gilts: the means by which the Government borrows money from private investors.
The gilt market later stabilised somewhat as the reasoning behind the Treasury’s decision-making became apparent.
Among those who welcomed suggestions the tax rise had been abandoned was Health Secretary Wes Streeting.
He told PA: “What I would say about this morning is, it is really important that we keep the promises that we made to the public at the last general election.
“Our economy was broken by the Conservatives, so were our public services, but so was trust in politics itself.
“Our job is to rebuild the economy, rebuild our public services, and rebuild trust in politics.”
Helen Miller, director of the Institute for Fiscal Studies (IFS) think tank, said it was “not unusual” for chancellors to make last-minute changes to their Budget plans.
She added: “But the news that Rachel Reeves has backed away from a plan to increase the rates of income tax will lead investors to worry that the Chancellor will instead increase a range of smaller taxes that can be more damaging to economic growth.
“They may also worry that the change of plans signals that this Government are reluctant to do politically difficult things.
“These are the kinds of concerns that can lead investors to demand higher returns when lending to the Government.”
If the Government does choose to raise a set of smaller taxes, they should also be reformed “so that they do less damage to growth”, the IFS chief said.
Business
Mark Zuckerberg arrives to testify in social media addiction trial
In one such case, 29 state attorney generals are pushing a California federal court to demand that the platforms make a number of changes immediately, before any trial, including forcing Meta to remove all accounts known to belong to users under 13 years of age.
Business
India eyes diversification of crude oil sources; Piyush Goyal says would ‘love’ high-quality coking coal from US – The Times of India
India is looking to diversify its sources of crude oil, Commerce Minister Piyush Goyal has said. Goyal’s comments assume significance in light of the India-US trade deal joint statement which lowers tariffs on Indian exports to 18%. The Donald Trump administration has also removed the 25% penal tariffs on India on the condition that it stops buying crude oil from Russia.India’s crude imports from Russia have dropped since the US imposed sanctions on two major Russian oil firms in late 2025. According to reports, the share of Russian crude in India’s oil imports has dropped to the lowest level since late 2022 and analysts expect the numbers to drop further in the coming months.
India would ‘love’ high-quality coking coal from US
Piyush Goyal said India is looking to broaden its sourcing of crude oil and coking coal and would welcome supplies of premium-quality coking coal from the United States.Also Read | 18% tariffs, boost to exports, agriculture protected: How India benefits from trade deal with US? Explained“We want to diversify our oil sources. I want to diversify the source of coking coal for example. I am dependent on 2 or 3 geographies (for that) and prices keep fluctuating. I would love to have American coking coal which is high quality coming to India,” he said according to a PTI report.He noted that the US is well positioned to supply several products that are critical for India’s economic growth, including graphics processing units used in artificial intelligence, infrastructure and equipment for data centres, and high-performance computing systems.Goyal said India can produce goods in areas where US manufacturers may not be competitive, while America can serve as an important provider of technology and investment capital.Also Read | Trump removes 25% penal tariff: What happens if India stops buying Russian crude oil?He added that demand for aircraft from the US is already estimated at about $100 billion over the next five years, with additional capacity required to expand domestic aviation and help lower fares.Under the proposed interim trade pact with the United States, India has conveyed its intent to procure goods worth $500 billion from America over the next five years. An Indian delegation is scheduled to travel to the US next week to conclude the legal drafting of the agreement, which is expected to be signed in March.Piyush Goyal said entering into a trade agreement with the US would be beneficial for India, noting that it would create significant opportunities for domestic businesses, particularly in labour-intensive sectors and technology-driven services.Referring to India’s free trade agreements, Goyal noted that nine such pacts have been concluded over the past four years. He added that these deals were negotiated from a position of confidence, emphasising that India now engages in trade talks assertively, without defensiveness, and with a focus on long-term interests.
Business
FDA chief Marty Makary says ‘everything should be over the counter’ unless drug is unsafe or addictive
Food and Drug Administration Commissioner Marty Makary told CNBC that he believes “everything should be over the counter” unless a drug is unsafe, addictive or requires monitoring – doubling down on a push that some in the pharmaceutical industry have questioned.
In an interview Wednesday in Washington, D.C., Makary said the FDA aims to make changes this year that allow more companies to offer their prescription medicines over the counter, or OTC. He noted that the agency is going through “the proper regulatory processes” to update OTC monographs – the rulebooks that determine which drugs can be sold without a prescription.
Makary said the FDA is looking at “basic, safe” prescription drugs like nausea medications and vaginal estrogen, which is used to treat menopausal symptoms like dryness and pain.
“In my opinion, everything should be over the counter and not requiring a prescription, unless it’s unsafe, unless you need laboratory tests to monitor how it’s being received by your body, or if it could be used for some nefarious purpose or it’s addictive,” Makary told CNBC after the PhRMA Forum, a one-day event organized by the pharmaceutical industry’s largest lobbying group.
“If it doesn’t meet those criteria, why shouldn’t a drug be over the counter? So we should be asking, why not? Instead of, ‘Oh, you want to move over the counter, you got to go through a long, tedious process,'” he added.
Marty Makary, U.S. President Donald Trump’s nominee to be U.S. Food and Drug Administration (FDA) commissioner, testifies before a Health, Education, Labor, and Pensions (HELP) Senate Committee confirmation hearing on Capitol Hill in Washington, D.C., U.S., March 6, 2025.
Kent Nishimura | Reuters
The FDA has long considered making some prescription drugs available OTC to improve accessibility, reduce health-care costs and help patients stay on their medications. For example, patients wouldn’t have to take time off work to see a doctor for a prescription or could refill a drug without delay.
Congress boosted the effort through legislation in November that streamlines the regulatory process for prescription-to-OTC transitions, including full, conditional and partial “switch” pathways.
Makary framed the FDA’s latest push to expand OTC access as another way to lower drug costs, a key priority of the Trump administration. He argued that placing medications directly on store shelves would bypass insurers and pharmacy benefit managers, eliminating the rebate-driven system that often obscures a drug’s true price.
He also said selling drugs over the counter promotes transparency that “keeps prices in check.” In some cases, Makary said cash prices for OTC medicines are lower than patients’ copays for prescription drugs “when there’s a money game going on behind the pharmacy counter,” with employers and insurers sharing the cost.
Pharma questions OTC push
Some in the pharmaceutical industry have pushed back on that argument. Most OTC drugs are not covered by insurance, meaning their prices could eclipse those of generic prescription medicines and potentially make them less affordable for patients who rely on coverage.
In comments to the FDA earlier this month, the Association for Accessible Medicines argued that “the shift of many prescription drugs to nonprescription status could actually increase costs to patients, thereby decreasing patient access to treatments.” That organization represents manufacturers and distributors of generic prescription medicines.
The FDA also doesn’t have the authority to regulate drug prices. In its own comments this month, PhRMA said the agency must respect “the core principle that pricing considerations may not factor into FDA regulatory decision-making.”
The Pharmaceutical Research and Manufacturers of America added that the FDA should not attempt to transition any prescription drugs to OTC without first consulting manufacturers. But the group emphasized that it supports the FDA’s effort to expand access to crucial medicines.
In its own comment this month, AstraZeneca said several previous attempts to transition cholesterol-cutting statins to OTC status have been “unsuccessful, with consumers consistently having difficulty making proper self-selection decisions.”
Meanwhile, Makary told CNBC on Wednesday that “we have to trust people to make their decisions. We’ve got to get away from this paternalistic mindset.”
The FDA removed the longtime director of the office of over-the-counter drugs, Theresa Michele, from her position in December, STAT news reported at the time.
-
Business1 week agoAye Finance IPO Day 2: GMP Remains Zero; Apply Or Not? Check Price, GMP, Financials, Recommendations
-
Fashion1 week agoComment: Tariffs, capacity and timing reshape sourcing decisions
-
Business1 week agoGold price today: How much 18K, 22K and 24K gold costs in Delhi, Mumbai & more – Check rates for your city – The Times of India
-
Business6 days agoTop stocks to buy today: Stock recommendations for February 13, 2026 – check list – The Times of India
-
Fashion7 days agoIndia’s PDS Q3 revenue up 2% as margins remain under pressure
-
Tech1 week agoRemoving barriers to tech careers
-
Fashion1 week agoSaint Laurent retains top spot as hottest brand in Q4 2025 Lyst Index
-
Politics6 days agoIndia clears proposal to buy French Rafale jets
